| HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study RL Hamers, CL Wallis, C Kityo, M Siwale, K Mandaliya, F Conradie, ... The Lancet infectious diseases 11 (10), 750-759, 2011 | 349 | 2011 |
| Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa KCE Sigaloff, RL Hamers, CL Wallis, C Kityo, M Siwale, P Ive, ME Botes, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 58 (1), 23-31, 2011 | 237 | 2011 |
| Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a … RL Hamers, R Schuurman, KCE Sigaloff, CL Wallis, C Kityo, M Siwale, ... The Lancet infectious diseases 12 (4), 307-317, 2012 | 236 | 2012 |
| Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority … JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ... The lancet HIV 5 (5), e211-e220, 2018 | 231 | 2018 |
| Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies RL Hamers, KCE Sigaloff, AM Wensing, CL Wallis, C Kityo, M Siwale, ... Clinical infectious diseases 54 (11), 1660-1669, 2012 | 199 | 2012 |
| Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa TS Boender, CM Kityo, RS Boerma, RL Hamers, P Ondoa, M Wellington, ... Journal of Antimicrobial Chemotherapy 71 (10), 2918-2927, 2016 | 122 | 2016 |
| Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa TS Boender, BM Hoenderboom, KCE Sigaloff, RL Hamers, M Wellington, ... Clinical Infectious Diseases 61 (11), 1749-1758, 2015 | 91 | 2015 |
| Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa KCE Sigaloff, RL Hamers, CL Wallis, C Kityo, M Siwale, P Ive, ME Botes, ... The Journal of infectious diseases 205 (11), 1739-1744, 2012 | 88 | 2012 |
| Cohort profile: the PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance—HIV drug resistance in sub-Saharan Africa and the Asia … RL Hamers, R Oyomopito, C Kityo, P Phanuphak, M Siwale, ... International journal of epidemiology 41 (1), 43-54, 2012 | 79 | 2012 |
| Safety and exposure of once‐daily ritonavir‐boosted atazanavir in HIV‐infected pregnant women F Conradie, C Zorrilla, D Josipovic, M Botes, O Osiyemi, E Vandeloise, ... HIV medicine 12 (9), 570-579, 2011 | 79 | 2011 |
| Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study SC Inzaule, RL Hamers, M Noguera-Julian, M Casadellą, M Parera, ... The Lancet HIV 5 (11), e638-e646, 2018 | 75 | 2018 |
| HIV–HBV coinfection in southern Africa and the effect of lamivudine-versus tenofovir-containing cART on HBV outcomes RL Hamers, HL Zaaijer, CL Wallis, M Siwale, P Ive, ME Botes, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 64 (2), 174-182, 2013 | 62 | 2013 |
| Protease inhibitor resistance in the first 3 years of second-line antiretroviral therapy for HIV-1 in sub-Saharan Africa TS Boender, RL Hamers, P Ondoa, M Wellington, C Chimbetete, ... The Journal of infectious diseases 214 (6), 873-883, 2016 | 57 | 2016 |
| Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a … P Cahn, R Kaplan, PE Sax, K Squires, JM Molina, A Avihingsanon, ... The lancet HIV 4 (11), e486-e494, 2017 | 53 | 2017 |
| Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings DA Cooper, J Heera, P Ive, M Botes, E Dejesus, R Burnside, N Clumeck, ... Aids 28 (5), 717-725, 2014 | 50 | 2014 |
| Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double … M Nelson, G Amaya, N Clumeck, C Arns da Cunha, D Jayaweera, ... Journal of antimicrobial chemotherapy 67 (8), 2020-2028, 2012 | 43 | 2012 |
| Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries KCE Sigaloff, RL Hamers, J Menke, M Labib, M Siwale, P Ive, ME Botes, ... Clinical infectious diseases 54 (suppl_4), S294-S299, 2012 | 32* | 2012 |
| Safeguarding the future of genomic research in South Africa: Broad consent and the Protection of Personal Information Act No. 4 of 2013 C Staunton, R Adams, M Botes, ES Dove, L Horn, M Labuschaigne, ... SAMJ: South African Medical Journal 109 (7), 468-470, 2019 | 31 | 2019 |
| PharmAccess African Studies to Evaluate Resistance (PASER). HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral … RL Hamers, CL Wallis, C Kityo, M Siwale, K Mandaliya, F Conradie, ... Lancet Infect Dis 11 (10), 750-9, 2011 | 30 | 2011 |
| The MERIT study of maraviroc in antiretroviral-naive patients with R5 HIV-1: 96-week results J Heera, P Ive, M Botes, E DeJesus, H Mayer, J Goodrich, N Clumeck, ... 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22, 2009 | 29 | 2009 |
Martin S OlivierProfessor of Computer Science, University of PretoriaVerified email at cs.up.ac.za
